Several listed companies in Shanghai and Shenzhen issued important announcements on January 17. The following is a summary of good news:
Konka Group Co.Ltd(000016) : the holding subsidiary plans to increase capital and shares and introduce strategic investors
Konka Group Co.Ltd(000016) (000016) it was announced on January 17 that the holding Sun Company Hefei kangxinwei Storage Technology Co., Ltd. plans to increase its capital and shares by means of public listing in the state-owned property exchange, and introduce strategic investors. It is expected that the amount of capital increase will be 150-250 million yuan. Hefei kangxinwei is mainly engaged in the design and sales of memory master chips.
Zhejiang Dayang Biotech Group Co.Ltd(003017) : projects with an annual output of 25000 tons of potassium carbonate (phased) have been completed and passed the environmental protection acceptance
Zhejiang Dayang Biotech Group Co.Ltd(003017) (003017) on January 17, it was announced that the company’s project with an annual output of 25000 tons of potassium carbonate and 15000 tons of potassium bicarbonate (phased) was completed and passed the environmental protection acceptance, indicating that the company’s comprehensive annual capacity of potassium carbonate (including potassium bicarbonate equivalent) increased from 77000 tons in 2020 to 85000 tons at the end of 2021, providing capacity support for the growth of the company’s operating performance.
Keda Industrial Group Co.Ltd(600499) : the extended application of ceramic machinery products is under way, and the existing lithium salt tunnel kiln order
Keda Industrial Group Co.Ltd(600499) (600499) said on the interactive platform that the company is actively carrying out the extended application of ceramic machinery products. There are orders for lithium salt tunnel kiln. At present, this part of the business accounts for a relatively small proportion. Lanke currently has a 20000 ton battery grade lithium carbonate production line. After the lithium precipitation unit is put into operation, it will produce battery grade lithium carbonate.
Jilin Aodong Pharmaceutical Group Co.Ltd(000623) : the holding subsidiary obtained the listing Filing Certificate of traditional Chinese medicine formula granules
Jilin Aodong Pharmaceutical Group Co.Ltd(000623) (000623) it was announced on January 17 that Yanbian pharmaceutical, the holding subsidiary of the company, obtained 91 national standard listing and filing certificates for traditional Chinese medicine formula granules, which is of great significance for the company to expand the business of traditional Chinese medicine formula granules. In the future, the company will carry out the production and sales of the above products in combination with the market situation.
Zhejiang Xianju Pharmaceutical Co.Ltd(002332) : it is proposed to build a production line of 20 million injections and 200 million capsules
Zhejiang Xianju Pharmaceutical Co.Ltd(002332) (002332) announced on January 17 that it is planned to invest in the construction of a production line with an annual output of 20 million injections and 200 million capsules, with a total planned investment of 120 million yuan. After the completion of the project, it is conducive to the development of the company’s products in the direction of preparation innovative products with good curative effect, low competition and high barriers, and enrich the preparation product line. In addition, it is proposed to publicly transfer 61.2% equity of Haisheng pharmaceutical, a holding subsidiary. Haisheng pharmaceutical is mainly engaged in vitamin D3 API manufacturing, food additive manufacturing, etc., and has no synergistic effect with the steroid hormone industry chain of the company.
Vantone Neo Development Group Co.Ltd(600246) : it is proposed to repurchase shares of RMB 150 million to RMB 300 million
Vantone Neo Development Group Co.Ltd(600246) (600246) announced on January 17 that it is planned to repurchase shares with RMB 150 million to RMB 300 million, the repurchase price shall not exceed RMB 15.16/share, and all the repurchased shares will be used for employee stock ownership plan or equity incentive.
Shanghai Longyun Cultural Creation & Technology Group Co.Ltd(603729) : the shareholder Zhuo Shuying and the persons acting in concert intend to increase their holdings of the company’s shares
Shanghai Longyun Cultural Creation & Technology Group Co.Ltd(603729) (603729) announced on January 17 that Zhuo Shuying, a shareholder holding more than 5% of the company’s shares, and the persons acting in concert intend to increase their holdings of no less than 1% of the company’s shares by means of centralized bidding transaction, and there is no price range for this increase.
Shuangliang Eco-Energy Systems Co.Ltd(600481) : signed a silicon wafer procurement framework contract with Tongwei Cecep Solar Energy Co.Ltd(000591)
Shuangliang Eco-Energy Systems Co.Ltd(600481) (600481) announced on January 17 that the wholly-owned subsidiary Shuangliang silicon materials (Baotou) Co., Ltd. signed a silicon wafer procurement framework contract with Tongwei Cecep Solar Energy Co.Ltd(000591) (Chengdu) Co., Ltd. the contract agreed to purchase 1.048 billion monocrystalline silicon wafers from the wholly-owned subsidiary of the company from January 2022 to December 2024, with an estimated sales amount of 6.305 billion yuan.
Frontier Biotechnologies Inc(688221) : the product under development fb2001 is intended to treat hospitalized patients with moderate and severe covid-19 pneumonia
Frontier Biotechnologies Inc(688221) (688221) announced on the 17th that the company’s product fb2001 under development is a covid-19 pneumonia virus protease inhibitor for injection, and the target is covid-19 pneumonia virus 3CL main protease. The product under development is intended to treat hospitalized patients with moderate and severe covid-19 pneumonia. New drug research and development is a long-term work, and the sales of new drugs after listing is affected by multiple factors. Up to now, Pfizer’s oral covid-19 drug (paxlovid) has been authorized by the U.S. Food and Drug Administration for emergency use to treat non hospitalized patients with mild to moderate covid-19 pneumonia with adverse prognosis risk.
Shandong Jiangquan Industry Co.Ltd(600212) : disclose the plan for the sale of major assets and plan to withdraw from the thermal power business
Shandong Jiangquan Industry Co.Ltd(600212) (600212) on January 17, it disclosed the plan for the sale of major assets, and planned to transfer the thermoelectric business asset group owned by the company to Linyi Xuyuan Investment Co., Ltd. in cash; At present, the audit and evaluation related to the transaction have not been fully completed, and it is expected that there will be a major asset restructuring. After the completion of the transaction, the company will strategically withdraw from the thermal power business, concentrate resources on strategic and business transformation, and focus on the business layout focusing on new energy charging and energy storage business.
Shanghai Yatong Co.Ltd(600692) : the proposed new energy company will not have a significant impact on the company’s business structure in the short term
Shanghai Yatong Co.Ltd(600692) (600692) announced on January 17 that the company plans to invest 19 million yuan to establish Shanghai Yatong New Energy Technology Co., Ltd. to carry out the construction and operation of Cecep Solar Energy Co.Ltd(000591) photovoltaic power station project in Chongming district. This investment will help the company to further explore new profit growth points. According to the company’s latest financial report, real estate development is still the company’s main business. In 2020, real estate sales accounted for 64.9% of the company’s operating revenue. The new energy company will not have a significant impact on the company’s business structure in the short term.
Lb Group Co.Ltd(002601) : it is proposed to invest in projects such as electronic grade lithium iron phosphate with an annual output of 150000 tons
Lb Group Co.Ltd(002601) (002601) it was announced on January 17 that Hubei bailiwanrun new energy Co., Ltd., the holding subsidiary of the company, plans to invest 2 billion yuan in the construction of an electronic grade lithium iron phosphate project with an annual output of 150000 tons; Longbai Xiangyang, a wholly-owned subsidiary, plans to invest 1 billion yuan in the construction of a post-treatment project with an annual output of 200000 tons of titanium dioxide; Yunnan Guoti, a holding subsidiary, plans to invest 441 million yuan to build an innovation project for the upgrading and transformation of 10000 tons of sponge titanium production line.
